Description:
This randomized, open-label study was designed to evaluate and compare the safety and
efficacy of atezolizumab with gemcitabine + cisplatin or carboplatin in PD-L1 selected
participants with chemotherapy-naive, Stage IV squamous NSCLC. The study was closed due to
low patient enrollment and the Sponsor's decision to include patients with squamous NSCLC
into the GO29431 study, NCT02409342. Therefore the planned objectives of this study are no
longer applicable and formal analyses of efficacy or safety have not been performed.
Title
- Brief Title: A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)
- Official Title: A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With Gemcitabine+Cisplatin or Carboplatin for PD-L1-Selected, Chemotherapy Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer
Clinical Trial IDs
- ORG STUDY ID:
GO29432
- SECONDARY ID:
2014-003106-33
- NCT ID:
NCT02409355
Conditions
- Non-Small Cell Lung Cancer
Interventions
Drug | Synonyms | Arms |
---|
Atezolizumab | MPDL3280A; Tecentriq | Atezolizumab |
Carboplatin | | Gemcitabine + Cisplatin/Carboplatin |
Cisplatin | | Gemcitabine + Cisplatin/Carboplatin |
Gemcitabine | | Gemcitabine + Cisplatin/Carboplatin |
Purpose
This randomized, open-label study was designed to evaluate and compare the safety and
efficacy of atezolizumab with gemcitabine + cisplatin or carboplatin in PD-L1 selected
participants with chemotherapy-naive, Stage IV squamous NSCLC. The study was closed due to
low patient enrollment and the Sponsor's decision to include patients with squamous NSCLC
into the GO29431 study, NCT02409342. Therefore the planned objectives of this study are no
longer applicable and formal analyses of efficacy or safety have not been performed.
Trial Arms
Name | Type | Description | Interventions |
---|
Atezolizumab | Experimental | Participants will receive intravenous (IV) infusion of atezolizumab once on Day 1 of each 21-day cycle until loss of clinical benefit. | |
Gemcitabine + Cisplatin/Carboplatin | Active Comparator | Participants will receive IV infusion of gemcitabine + cisplatin or gemcitabine + carboplatin once on Day 1 of each 21-day cycle for four or six cycles as per local standard of care. | - Carboplatin
- Cisplatin
- Gemcitabine
|
Eligibility Criteria
Inclusion Criteria:
- Histologically or cytologically confirmed Stage IV squamous NSCLC
- Tumor programmed death-ligand 1 (PD-L1) expression, as determined by
immunohistochemistry (IHC) assay of archival tumor tissue or tissue obtained at
screening
- No prior treatment for Stage IV squamous NSCLC
- Measurable disease as defined by RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Adequate hematologic and end-organ function
Exclusion Criteria:
- Active or untreated central nervous system (CNS) metastases
- Untreated or inadequately treated spinal cord compression
- Leptomeningeal disease
- Uncontrolled pleural effusion, pericardial effusion, or ascites
- Uncontrolled tumor-related pain
- Uncontrolled hypercalcemia
- Any other malignancies within 5 years except those with negligible risk of metastasis
or death
- Pregnant or lactating women
- Known hypersensitivity to any component of atezolizumab formulation or other study
medication
- History of autoimmune disease except controlled, treated hypothyroidism or type I
diabetes
- Prior allogeneic bone marrow or solid organ transplantation
- Positive human immunodeficiency virus (HIV) test
- Active hepatitis B or C
- Active tuberculosis
- Significant cardiovascular disease
- Severe infection or major surgery within 4 weeks prior to randomization
- Use of any approved anti-cancer therapy within 3 weeks prior to treatment
- Use of an investigational agent or participation in another clinical trial within 4
weeks prior to randomization
- Exposure to oral or IV antibiotics within 2 weeks or live attenuated vaccines within 4
weeks prior to randomization
- Prior treatment with cluster of differentiation (CD) 137 agonists or immune checkpoint
blockade therapies, anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic
antibodies
- Treatment with immunostimulatory agents within 4 weeks or immunosuppressive agents
within 2 weeks prior to randomization
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) |
Time Frame: | Baseline up to death or disease progression, whichever occurs first (up to approximately 2.5 years) |
Safety Issue: | |
Description: | |
Details
Phase: | Phase 3 |
Primary Purpose: | Interventional |
Overall Status: | Terminated |
Lead Sponsor: | Hoffmann-La Roche |
Last Updated
February 15, 2019